Close Menu

NEW YORK (GenomeWeb) – IncellDx today announced it received CE marking for it flow cytometry-based test for human papillomavirus.

The company also announced the launch of the test, which combines the quantification of oncogene mRNA overexpression, proliferation, and aneuploidy in one high-throughput assay. It quantifies the E6/E7 mRNA overexpression by RNA in situ hybridization and combines it with cell cycle DNA, which quantifies proliferation, which IncellDx said is a hallmark of transformation to cancer.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Two researchers are calling for education for scientists on defending facts.

Researchers were among those who marched in London this weekend to call for another vote on Brexit.

Duke has agreed to pay $112.5 million to settle a lawsuit regarding its handling of data falsified by biologist Erin Potts-Kant. 

In PLOS this week: genetic factors influencing inorganic arsenic metabolism and toxicity, a germline variant in the cell adhesion molecule-coding gene DSCAM, and more.